NEOALTTO

Clinical Trial Program

A randomized, multicenter open-label Phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2-positive primary breast cancer.

Phase III

Status

Finished

Tumour subtype:

HER2+

Scenario

Neoadjuvant

SPONSOR

GlaxoSmithKline

COLLABORATORS

Breast International Group

PRINCIPAL INVESTIGATORS

José Baselga, MD, PhD (Memorial Sloan Kettering Cancer Center)
Holger Eidtmann, MD (University Medical Center Schleswig-Holstein Campus Kiel)

Sites

HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA, HOSPITAL RAMON Y CAJAL, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE